Monsanto licenses use of Cellectis' genome modification technology
Monsanto Company announced a non-exclusive research and commercial license agreement with Cellectis S.A. for broad use of its meganuclease technology in plants.
Meganucleases are molecular scissors that can be directed to a single site in the genome of a plant cell, thereby allowing a wide range of precise genome modifications, including gene stacking, gene knock-out as well as modulation of gene function to develop new traits. Under the agreement, Monsanto will have access to Cellectis’ intellectual property on meganucleases and its custom meganuclease production platform.
Cellectis will receive an upfront payment of €3 million, and subject to the approval of the Extraordinary General Meeting of Cellectis’ shareholders, Monsanto will make an equity investment of €1 million to allow Cellectis to scale the technology for agriculture. Cellectis will also be eligible to receive fees for the development of each meganuclease, success-based milestones and may receive royalties on certain traits commercialized by Monsanto. Further financial details of the agreement were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.